SANGAMO THERAPEUTICS INC (SGMO) Stock Income Statement
NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.24M | 57.80M | 176.23M | 111.30M | 110.70M | |||
| Minority Interest Expense | N/A | N/A | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 192.31M | 155.95M | 278.82M | 312.60M | 294.00M | |||
| Research and Development | 137.53M | 111.42M | 221.66M | 249.90M | 230.80M | |||
| Selling, General, and Administrative Expenses | 54.79M | 44.53M | 57.17M | 62.70M | 63.20M | |||
| Operating Income | -128.08M | -98.15M | -102.59M | -201.30M | -183.30M | |||
| Interest Income/Expense | 6.17M | 5.86M | 11.10M | 9.40M | 5.30M | |||
| Non Recurring Items | -5.52M | -5.82M | -171.41M | N/A | N/A | |||
| Income Before Taxes | -128.59M | -98.11M | -262.90M | -191.80M | -178.00M | |||
| Income Tax | -48.00K | -167.00K | -5.07M | 400.00K | 300.00K | |||
| Net Income | -128.54M | -97.94M | -257.83M | -192.30M | -178.30M | |||
| EBITDA | -123.36M | -93.04M | -87.53M | -189.20M | -173.90M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.62 | -0.49 | -1.48 | -1.25 | -1.23 | |||
| Non GAAP EPS | -0.39 | -0.52 | -1.47 | -1.25 | -1.24 | |||
| Statistics | ||||||||
| Profit Margin | -200.10% | -169.45% | -146.30% | -172.78% | -161.07% | |||
| Operating Profit Margin | -199.38% | -169.81% | -58.21% | -180.86% | -165.58% | |||
All data in USD